142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

297108
Kidney cancer incidence and mortality among American Indians and Alaska Natives in the United States, 1990-2009

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Tuesday, November 18, 2014 : 8:50 AM - 9:10 AM

Jun Li, MD, PhD , Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA
Hannah Weir, PhD , Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA
Melissa Jim, MPH , Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Albuquerque, NE
Sallyann King, MD , Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA
Reda Wilson , Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA
Viraj Master , Emory University, atlanta, GA
Objective. kidney cancer incidence has continued to increase in the United States for all racial/ethnic groups. American Indians and Alaska Natives (AI/ANs), both men and women, are at greater risk of developing and dying of kidney cancers than other racial/ethnic groups. The objective of this study was to describe rates and trends in kidney cancer incidence and mortality and identify disparities between non-Hispanic AI/ANs and non-Hispanic white (NHW) populations.

Methods. To minimize the misclassification of race, Indian Health Service (IHS) patient registration database was linked to cancer registry records and National Death Index (NDI). We calculated age-adjusted kidney cancer incidence (2001-2009) and death rates (1990-2009), rate ratios, annual percent change (APC), and corresponding 95% confidence intervals (CIs)  by sex, age, and Indian Health Service (IHS) region in the Contract Health Service Delivery Area (CHSDA) Counties.  

Results. There were 2,088 AI/AN kidney cancer cases diagnosed from 2001-2009 and 1,215 non-Hispanic AI/AN kidney cancer deaths from 1990-2009 in the CHSDA counties. Non-Hispanic AI/ANs have a 1.6-fold higher kidney cancer incidence and a 1.9-fold higher kidney cancer death rate than NHWs. Despite a significant decline over the past twenty years in kidney cancer death rates for NHW (APC=-0.3; 95% CI=-0.5, 0.0), death rates for non-Hispanic AI/ANs remained stable (APC=0.4; 95% CI=-0.7, 1.5). Incidence rates of kidney cancer continue to rise, but more rapidly for non-Hispanic AI/ANs (APC=3.5; 95% CI=1.2, 5.8) than NHWs (APC=2.1; 95% CI=1.4, 2.8).

Conclusions. Non-Hispanic AI/ANs have greater risk of developing and dying of kidney cancers. Incidence rates have increased faster in non-Hispanic AIAN compared to NHW.  Death rates have decreased significantly in NHW, but remained stable in non-Hispanic AI/AN. Racial disparities in kidney cancer are widening.

Learning Areas:

Diversity and culture
Epidemiology
Public health or related education
Public health or related research

Learning Objectives:
Describe rates and trends in kidney cancer incidence and mortality and identify cancer disparities between non-Hispanic AI/ANs and non-Hispanic whites

Keyword(s): Cancer, Health Disparities/Inequities

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: blank

Qualified on the content I am responsible for because: Wroking in the federal government, I have been the principal of multiple grants focusing on the epidemiology of cancer prevention and control including kidney cancer. My scientific interests have been the development of strategies to reduce cancer health disparities.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.